Clinical evidence of the relationship between aspirin and breast cancer risk (Review)

Jacobo-Herrera, Nadia; Pérez‐Plasencia, Carlos; Camacho-Zavala, Elizabeth; Figueroa‐González, Gabriela; López–Urrutia, Eduardo; García-Castillo, Verónica; Zentella‐Dehesa, Alejandro

doi:10.3892/or.2014.3270

Cited by 18 publications

(9 citation statements)

References 62 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, a recent clinical analysis reported that regular aspirin use was associated with a lower risk of cancer-specific mortality in individuals already diagnosed with colorectal cancer [ 183 ]. Similar observations have been reported for the chemopreventive role of aspirin in breast cancer [ 184 , 185 ]. Together, these results suggested that the chemopreventive benefits of aspirin might only manifest after long-term continuous administration.…”

Section: Therapeutic Insights From Mouse Modelssupporting

confidence: 89%

Manipulation of DNA Repair Proficiency in Mouse Models of Colorectal Cancer

McIlhatton

Boivin

Groden

2016

BioMed Research International

View full text Add to dashboard Cite

Technical and biological innovations have enabled the development of more sophisticated and focused murine models that increasingly recapitulate the complex pathologies of human diseases, in particular cancer. Mouse models provide excellent in vivo systems for deciphering the intricacies of cancer biology within the context of precise experimental settings. They present biologically relevant, adaptable platforms that are amenable to continual improvement and refinement. We discuss how recent advances in our understanding of tumorigenesis and the underlying deficiencies of DNA repair mechanisms that drive it have been informed by using genetically engineered mice to create defined, well-characterized models of human colorectal cancer. In particular, we focus on how mechanisms of DNA repair can be manipulated precisely to create in vivo models whereby the underlying processes of tumorigenesis are accelerated or attenuated, dependent on the composite alleles carried by the mouse model. Such models have evolved to the stage where they now reflect the initiation and progression of sporadic cancers. The review is focused on mouse models of colorectal cancer and how insights from these models have been instrumental in shaping our understanding of the processes and potential therapies for this disease.

show abstract

Section: Therapeutic Insights From Mouse Modelssupporting

confidence: 89%

Manipulation of DNA Repair Proficiency in Mouse Models of Colorectal Cancer

McIlhatton

Boivin

Groden

2016

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…However, these results must be interpreted carefully, as exposure categories have been defined heterogeneously among the studies which have weakened the validity of the pooled estimates. In addition, Mangiapane S [5] and Jacobo-Herrera NJ [22] have pointed out that the relationship between breast cancer and aspirin, dosage, time and frequency of aspirin use have yet to be established. Therefore, it is necessary to perform this dose-response meta-analysis with cohort design to offer a more confident and exhaustive solution to a possible inverse association between breast cancer risk and aspirin intake [22].…”

Section: Discussionmentioning

confidence: 99%

Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants

Shi

Zeng

et al. 2017

Oncotarget

View full text Add to dashboard Cite

BackgroundPrevious meta-analyses on the relationship between aspirin use and breast cancer risk have drawn inconsistent results. In addition, the threshold effect of different doses, frequencies and durations of aspirin use in preventing breast cancer have yet to be established.ResultsThe search yielded 13 prospective cohort studies (N=857,831 participants) that reported an average of 7.6 cases/1,000 person-years of breast cancer during a follow-up period of from 4.4 to 14 years. With a random effects model, a borderline significant inverse association was observed between overall aspirin use and breast cancer risk, with a summarized RR = 0.94 (P = 0.051, 95% CI 0.87-1.01). The linear regression model was a better fit for the dose-response relationship, which displayed a potential relationship between the frequency of aspirin use and breast cancer risk (RR = 0.97, 0.95 and 0.90 for 5, 10 and 20 times/week aspirin use, respectively). It was also a better fit for the duration of aspirin use and breast cancer risk (RR = 0.86, 0.73 and 0.54 for 5, 10 and 20 years of aspirin use).MethodsWe searched MEDLINE, EMBASE and CENTRAL databases through early October 2016 for relevant prospective cohort studies of aspirin use and breast cancer risk. Meta-analysis of relative risks (RR) estimates associated with aspirin intake were presented by fixed or random effects models. The dose-response meta-analysis was performed by linear trend regression and restricted cubic spline regression.ConclusionOur study confirmed a dose-response relationship between aspirin use and breast cancer risk. For clinical prevention, long term (>5 years) consistent use (2-7 times/week) of aspirin appears to be more effective in achieving a protective effect against breast cancer.

show abstract

“…Prostaglandin synthesis through arachidonic acid and the possible effects of cyclooxygenase inhibitors as chemopreventive agents of breast cancer by the intracellular accumulation of arachidonic acid, which directly promotes apoptosis and attenuation of positive feedback for proliferation and survival. COX, cyclooxygenase; COXIBs, COX2 selective inhibitors; PG, prostaglandin; TXA 2 , thromboxane A 2 ( Jacobo-Herrera et al , 2014 ).…”

Section: Introductionmentioning

confidence: 99%

The potential contribution of dietary factors to breast cancer prevention

Shapira

2017

European Journal of Cancer Prevention

View full text Add to dashboard Cite

Breast cancer (BC), the leading cancer in women, is increasing in prevalence worldwide, concurrent with western metabolic epidemics, that is, obesity, metabolic syndrome, and diabetes, and shares major risk factors with these diseases. The corresponding potential for nutritional contributions toward BC prevention is reviewed and related to critical stages in the life cycle and their implications for carcinogenic and pathometabolic trajectories. BC initiation potentially involves diet-related pro-oxidative, inflammatory, and procarcinogenic processes, that interact through combined lipid/fatty acid peroxidation, estrogen metabolism, and related DNA-adduct/depurination/mutation formation. The pathometabolic trajectory is affected by high estrogen, insulin, and growth factor cascades and resultant accelerated proliferation/progression. Anthropometric risk factors – high birth weight, adult tallness, adiposity/BMI, and weight gain – are often reflective of these trends. A sex-based nutritional approach targets women’s specific risk in western obesogenic environments, associated with increasing fatness, estrogen metabolism, n-6 : n-3 polyunsaturated fatty acid ratio, and n-6 polyunsaturated fatty acid conversion to proinflammatory/carcinogenic eicosanoids, and effects of timing of life events, for example, ages at menarche, full-term pregnancy, and menopause. Recent large-scale studies have confirmed the effectiveness of the evidence-based recommendations against BC risk, emphasizing low-energy density diets, highly nutritious plant-based regimes, physical activity, and body/abdominal adiposity management. Better understanding of dietary inter-relationships with BC, as applied to food intake, selection, combination, and processing/preparation, and recommended patterns, for example, Mediterranean, DASH, plant-based, low energy density, and low glycemic load, with high nutrient/phytonutrient density, would increase public motivation and authoritative support for early/timely prevention, optimally merging with other dietary/health goals, for lifelong BC prevention.

show abstract

Clinical evidence of the relationship between aspirin and breast cancer risk (Review)

Cited by 18 publications

References 62 publications

Manipulation of DNA Repair Proficiency in Mouse Models of Colorectal Cancer

Manipulation of DNA Repair Proficiency in Mouse Models of Colorectal Cancer

Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants

The potential contribution of dietary factors to breast cancer prevention

Contact Info

Product

Resources

About